Stockscreener 앱 받기
15.92
0.03%
0.0052
전일 마감가:
$15.91
열려 있는:
$15.98
하루 거래량:
2.26M
Relative Volume:
0.75
시가총액:
$50.29B
수익:
$29.91B
순이익/손실:
$1.30B
주가수익비율:
39.24
EPS:
0.4056
순현금흐름:
$3.49B
1주 성능:
+2.88%
1개월 성능:
-0.28%
6개월 성능:
+0.98%
1년 성능:
+5.40%
1일 변동 폭
$15.87
$16.04
1주일 범위
$15.50
$16.04
52주 변동 폭
$12.99
$18.89
다케다약품공업 ADR Stock (TAK) Company Profile
명칭
Takeda Pharmaceutical Co Adr
전화
-
주소
-
Compare TAK vs HLN, TEVA, ZTS, UTHR
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
TAK
Takeda Pharmaceutical Co Adr
|
15.91 | 50.27B | 29.91B | 1.30B | 3.49B | 0.4056 |
HLN
Haleon Plc Adr
|
9.29 | 40.72B | 14.54B | 2.22B | 2.58B | 0.4871 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
33.33 | 38.67B | 17.53B | 1.58B | 444.18M | 1.3457 |
ZTS
Zoetis Inc
|
74.14 | 31.90B | 9.51B | 2.64B | 2.14B | 6.0361 |
UTHR
United Therapeutics Corp
|
549.23 | 23.03B | 3.17B | 1.29B | 1.01B | 27.09 |
다케다약품공업 ADR Stock (TAK) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-04-08 | 업그레이드 | Bernstein | Mkt Perform → Outperform |
| 2026-01-13 | 재개 | Morgan Stanley | Overweight |
| 2025-04-02 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2023-03-16 | 업그레이드 | BofA Securities | Neutral → Buy |
| 2022-07-19 | 업그레이드 | Cowen | Market Perform → Outperform |
| 2021-10-07 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2021-04-19 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2019-11-01 | 개시 | Cowen | Market Perform |
| 2019-08-15 | 다운그레이드 | Daiwa Securities | Outperform → Neutral |
모두보기
다케다약품공업 ADR 주식(TAK)의 최신 뉴스
0A87 Forecast — Price Target — Prediction for 2027 - TradingView
TAK-755 from Takeda Pharmaceutical Co.enzyme replacement for a rare bleeding disorder - AD HOC NEWS
TKDA Forecast — Price Target — Prediction for 2027 - TradingView
Takeda Pharmaceutical Co. Ltd. Sponsored ADR Actuals & Estimates (LS:A1CWZF) - TradingView
A1CWZF Forecast — Price Target — Prediction for 2027 - TradingView
TAK/N Forecast — Price Target — Prediction for 2027 - TradingView
Takeda Pharmaceutical Co. Ltd. Unsponsored Brazilian Depository Receipt Repr 1 ADR - TradingView
Takeda Pharmaceutical Co. Ltd. Sponsored ADR Actuals & Estimates (GETTEX:TKDA) - TradingView
Takeda Pharmaceutical Company Limited (TAK) stock price, news, quote and history - Yahoo Finance UK
Takeda Pharmaceutical StockAnalyst sentiment and chart picture on Thursday - AD HOC NEWS
Why Takeda’s Entyvio subcutaneous dose is changing quiet routines for gut patients - AD HOC NEWS
Silence Therapeutics Stock Rises On Positive Blood Cancer Drug Data - Sahm
Takeda Pharmaceutical Co Ltd (TAK) Stock Price, Trades & News - GuruFocus
Takeda AI-Drug Shows Superior Skin Clearance Against Bristol-Myers' Med - Benzinga
Takeda zasocitinib beats deucravacitinib in Phase 3 psoriasis trial - grafa.com
Astellas Pharma Inc. (ALPMY) Stock Price, News, Quote & History - Yahoo Finance
Takeda Pharmaceutical (TAK) Posts Modest Gain: Support Holds, Resistance NearsDescending Triangle - newsline.com
Takeda (TAK) Edges Higher: Approaching Key Resistance Amid Steady Pharma DemandDemand Zone - newsline.com
Dell Upgraded, Costco Downgraded: Updated Rankings on Top Blue-Chip Stocks - InvestorPlace
Takeda Pharmaceutical (ADR) stock (US8740602052): shares fall in New York after shelf registration u - AD HOC NEWS
Takeda (TAK) Stock Slips 1.18% as Shares Approach Key Support AreaShort Setup Alerts - newsline.com
TAK Stock Price, Quote & Chart | TAKEDA PHARMACEUTIC-SP ADR (NYSE:TAK) - ChartMill
Takeda Pharmaceutical (TAK) Holds Steady at $16.15 Amid Sideways TradingEarnings Miss Risk - newsline.com
Takeda Pharmaceutical (TAK) Faces Resistance at $16.73, Slips 2% Amid Sector WeaknessETF Liquidity - Newser
Takeda Pharmaceutical Co Ltd (FRA:TKDA) Stock Price, Trades & News - GuruFocus
Takeda Pharmaceutical stock (JP3730800003): oncology and rare disease focus after latest earnings up - AD HOC NEWS
Earnings call transcript: Takeda beats EPS expectations in Q4 2025 - Investing.com
Earnings call transcript: Takeda beats EPS expectations in Q4 2025 By Investing.com - Investing.com Canada
Takeda Pharmaceutical stock (JP3730800003): earnings in focus as investors weigh legal risks - AD HOC NEWS
Takeda Pharmaceutical stock (JP3730800003): recent earnings and Rybelsus biosimilar plans in focus - Ad-hoc-news.de
Takeda Pharmaceutical Co Ltd stock (JP3730800003): earnings beat but softer EPS outlook - AD HOC NEWS
Takeda Ready to Resume Top-Line Growth With Refreshed Late-Stage Pipeline - Morningstar
Takeda Pharma ADR earnings beat by $0.03, revenue fell short of estimates - Investing.com Nigeria
Takeda Pharmaceutical stock (JP3730800003): FY2026 profit surges 77.7%, but FY2027 guidance signals - AD HOC NEWS
Takeda Surpasses Earnings Estimates Despite Revenue Miss - HarianBasis.co
What's Going On With Takeda Stock Wednesday?Takeda Pharmaceutical Co (NYSE:TAK) - Benzinga
Earnings call transcript: Takeda’s Q4 2025 performance highlights resilience - Investing.com
Takeda Pharmaceutical stock (JP3730800003): Q4 2026 earnings report released - AD HOC NEWS
다케다약품공업 ADR (TAK) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.49%
2.54%
자본화:
|
볼륨(24시간):